Advertisement

Breast Cancer Research and Treatment

, Volume 151, Issue 3, pp 639–652 | Cite as

Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis

  • William W. L. Wong
  • Lisa K. Hicks
  • Hong-Anh Tu
  • Kathleen I. Pritchard
  • Murray D. Krahn
  • Jordan J. Feld
  • Kelvin K. Chan
Epidemiology

Abstract

Most patients with hepatitis B virus (HBV) have no symptoms, and many are unaware of the infection. However, HBV can reactivate with immunosuppression; chemotherapy causes reactivation in 22 % of hepatitis B surface antigen-positive patients. HBV reactivation can be fatal. HBV reactivation can be prevented, provided that HBV is recognized prior to chemotherapy. The objective of this study is to estimate the health and economic effects of HBV screening strategies in patients receiving adjuvant chemotherapy for breast cancer. We developed a state-transition microsimulation model to examine the cost-effectiveness of three HBV screening strategies: (1) “No screening”; (2) “Screen-and-Treat to prevent reactivation” (screen-all) with either lamivudine/tenofovir (LAM/TDF) or entecavir (ETV); and (3) “Screen-and-Treat high-risk only” (screen-HR) and treat with either LAM/TDF or ETV. Model data were obtained from the published literature. We used a payer’s perspective, a lifetime horizon, and a 5 % discount rate for the analysis. “Screen-all” would prevent at least 38 severe reactivations per 100,000 persons screened over the lifetime of the cohort. “Screen-all” was associated with an increase of 0.0034–0.0035 QALYs and an additional cost of C$164–C$266 per person, which translated into an incremental cost-effectiveness ratio of C$47,808/QALY–C$76,527/QALY gained compared with “No screening” depending on the antiviral therapy received. “Screen-all” was the most cost-effective strategy, while “Screen-HR” was inferior in all scenarios tested. HBV screening before adjuvant chemotherapy for breast cancer patients would prevent a significant number of reactivations, would likely be moderately cost-effective, and may extend the lives of breast cancer patients.

Keywords

Hepatitis B reactivation Cost-effectiveness Early-stage breast cancer Adjuvant chemotherapy 

Abbreviations

CHB

Chronic hepatitis B

HBV

Hepatitis B virus

HBsAg

Hepatitis B surface antigen

HBeAg

Hepatitis B “e” antigen

HCC

Hepatocellular carcinoma

ALT

Alanine transaminase

QALYs

Quality-adjusted life years

ICER

Incremental cost-effectiveness ratio

ETV

Entecavir

TDF

Tenofovir

LAM

Lamivudine

Notes

Acknowledgments

This study was supported by Canadian Breast Cancer Foundation (CBCF) Ontario.

Conflict of interest

Dr. Hicks, Dr. Feld, and Dr. Chan have received grant support from Gilead Sciences. Dr. Pritchard has received consulting fee support from Sanofi-Aventis, AstraZeneca, Pfizer, Roche, Amgen, Novartis, GSK, Boehringer Ingelheim, Genomic Health, and Eisai. Other authors declare that they have no conflict of interest.

Ethical standards

This study was conducted in compliance with the current laws of Canada.

Supplementary material

10549_2015_3382_MOESM1_ESM.docx (144 kb)
Supplementary material 1 (DOCX 144 kb)

References

  1. 1.
    Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol 13:790–801CrossRefPubMedGoogle Scholar
  2. 2.
    Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792CrossRefPubMedGoogle Scholar
  3. 3.
    Bonneterre J, Roche H, Kerbrat P, Bremond A, Fumoleau P, Namer M et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686–2693CrossRefPubMedGoogle Scholar
  4. 4.
    G. Early Breast Cancer Trialists’ Collaborative, Peto R, Davies C, Godwin J, Gray R, Pan HC et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444CrossRefGoogle Scholar
  5. 5.
    Wong WW, Woo G, Heathcote EJ, Krahn M (2013) Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol 27:137–147PubMedCentralPubMedGoogle Scholar
  6. 6.
    Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37:705–712CrossRefPubMedGoogle Scholar
  7. 7.
    Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC et al (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447–449CrossRefPubMedGoogle Scholar
  8. 8.
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188PubMedGoogle Scholar
  9. 9.
    Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977PubMedGoogle Scholar
  10. 10.
    Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS et al (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742–1749CrossRefPubMedGoogle Scholar
  11. 11.
    Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519–528CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Rotermann M, Langlois K, Andonov A, Trubnikov M (2013) Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Health Rep 24(11):3–13PubMedGoogle Scholar
  13. 13.
    “TreeAge (2013) Professional” Williamstown, MA: TreeAge Software, 2013Google Scholar
  14. 14.
    Benvegnu L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53:744–749CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65–73CrossRefPubMedGoogle Scholar
  16. 16.
    Chu CM, Liaw YF (2007) Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 14:147–152CrossRefPubMedGoogle Scholar
  17. 17.
    Craxi A, Colombo P, D’Amico G, Di Blasi F, Di Marco V, Magrin S et al (1987) Hepatitis B infection and liver cirrhosis: a reappraisal from the Mediterranean area. Ann Ist Super Sanita 24:257–265PubMedGoogle Scholar
  18. 18.
    D’Amico G, Morabito A, Pagliaro L, Marubini E (1986) Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31:468–475CrossRefPubMedGoogle Scholar
  19. 19.
    Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P et al (1995) Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis. Hepatology 21:77–82PubMedGoogle Scholar
  20. 20.
    Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E (2002) Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97:2886–2895CrossRefPubMedGoogle Scholar
  21. 21.
    Hutton DW, Tan D, So SK, Brandeau ML (2007) Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 147:460–469CrossRefPubMedGoogle Scholar
  22. 22.
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678–686CrossRefPubMedGoogle Scholar
  23. 23.
    Jacobs RJ, Saab S, Meyerhoff AS (2003) The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health 51:227–236CrossRefPubMedGoogle Scholar
  24. 24.
    Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS et al (2006) Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 101:2076–2089CrossRefPubMedGoogle Scholar
  25. 25.
    Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM (2005) Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 142:821–831CrossRefPubMedGoogle Scholar
  26. 26.
    Liaw YF, Tai DI, Chu CM, Chen TJ (1988) The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8:493–496CrossRefPubMedGoogle Scholar
  27. 27.
    Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ et al (1986) Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 90:263–267PubMedGoogle Scholar
  28. 28.
    Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF (1999) Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29:971–975CrossRefPubMedGoogle Scholar
  29. 29.
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML et al (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808–816CrossRefPubMedGoogle Scholar
  30. 30.
    Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA (1995) Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 274:1201–1208CrossRefPubMedGoogle Scholar
  31. 31.
    McMahon BJ, Holck P, Bulkow L, Snowball M (2001) Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 135:759–768CrossRefPubMedGoogle Scholar
  32. 32.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I et al (2011) Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 60:1109–1116CrossRefPubMedGoogle Scholar
  33. 33.
    Notifiable diseases on-line (Online) Public Health Agency of Canada, Ottawa.  http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/c_time-eng.php
  34. 34.
    Pisu M, Meltzer MI, Lyerla R (2002) Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine 21:312–321CrossRefPubMedGoogle Scholar
  35. 35.
    Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG (2008) Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther 27:1240–1252CrossRefPubMedGoogle Scholar
  36. 36.
    Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A et al (2007) Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 25:963–977CrossRefPubMedGoogle Scholar
  37. 37.
    Wen WH, Chang MH, Hsu HY, Ni YH, Chen HL (2004) The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr 144:397–399CrossRefPubMedGoogle Scholar
  38. 38.
    Yuen MF, Yuan HJ, Hui CK, Wong DK, Wong WM, Chan AO et al (2003) A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 52:416–419CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Younis T, Rayson D, Sellon M, Skedgel C (2008) Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat 111:261–267CrossRefPubMedGoogle Scholar
  40. 40.
    Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  41. 41.
    Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664–5671CrossRefPubMedGoogle Scholar
  42. 42.
    Gigi E, Lalla T, Orphanou E, Sinakos E, Vrettou E, Raptopoulou-Gigi M (2007) Long term follow-up of a large cohort of inactive HBsAg (+)/HBeAg (−)/anti-HBe (+) carriers in Greece. J Gastrointest Liver Dis 16:19–22Google Scholar
  43. 43.
    Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM et al (2002) Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35:1522–1527CrossRefPubMedGoogle Scholar
  44. 44.
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001–1010CrossRefPubMedGoogle Scholar
  45. 45.
    Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ (2010) Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51:422–430CrossRefPubMedGoogle Scholar
  46. 46.
    Ren FY, Piao DM, Piao XX (2007) A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 13:4264–4267CrossRefPubMedCentralPubMedGoogle Scholar
  47. 47.
    Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DKH et al (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139:1218–1229CrossRefPubMedGoogle Scholar
  48. 48.
    Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL et al (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52:886–893CrossRefPubMedGoogle Scholar
  49. 49.
    Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H et al (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98–107CrossRefPubMedGoogle Scholar
  50. 50.
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z et al (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011–1020CrossRefPubMedGoogle Scholar
  51. 51.
    Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z et al (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442–2455CrossRefPubMedGoogle Scholar
  52. 52.
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521–1531CrossRefPubMedGoogle Scholar
  53. 53.
    Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK et al (2012) Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 30:3167–3173CrossRefPubMedGoogle Scholar
  54. 54.
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J et al (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44:97–103CrossRefPubMedGoogle Scholar
  55. 55.
    Chu CM, Liaw YF (2006) Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26:142–152CrossRefPubMedGoogle Scholar
  56. 56.
    Fattovich G (2003) Natural history of hepatitis B. J Hepatol 39(Suppl 1):S50–S58CrossRefPubMedGoogle Scholar
  57. 57.
    Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A et al (1991) Natural history and prognostic factors for chronic hepatitis type B. Gut 32:294–298CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Villeneuve JP (2005) The natural history of chronic hepatitis B virus infection. J Clin Virol 34(Suppl 1):S139–S142CrossRefPubMedGoogle Scholar
  59. 59.
    Liaw YF (2009) Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 29(Suppl 1):100–107CrossRefPubMedGoogle Scholar
  60. 60.
    Fattovich G, Bortolotti F, Donato F (2008) Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48:335–352CrossRefPubMedGoogle Scholar
  61. 61.
    Grieco EM, Acosta YD, Cruz GP, Gambino C, Gryn T, Larsen LJ et al (2012) The foreign-born population in the United States: 2010. U.S. Department of Commerce, Economics and Statistics Administration, U.S. CENSUS BUREAU, Washington, DCGoogle Scholar
  62. 62.
    Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G et al (2010) The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 202:192–201CrossRefPubMedGoogle Scholar
  63. 63.
    Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146:473–481PubMedCentralPubMedGoogle Scholar
  64. 64.
    McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26:733–744CrossRefPubMedGoogle Scholar
  65. 65.
    (2005) Choosing interventions that are cost effective (WHO-CHOICE). World Health Organization, GenevaGoogle Scholar
  66. 66.
    Day FL, Karnon J, Rischin D (2011) Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29:3270–3277CrossRefPubMedGoogle Scholar
  67. 67.
    Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45:507–539CrossRefPubMedGoogle Scholar
  68. 68.
    Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL et al (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199–3202CrossRefPubMedGoogle Scholar
  69. 69.
    Hicks LK et al (2015) Estimating the risk of HBV reactivation in patients receiving chemotherapy for solid tumors: a metaanalysis, to be submittedGoogle Scholar
  70. 70.
    Gagnon YM, Levy AR, Iloeje UH, Briggs AH (2004) Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 38:S179–S186CrossRefPubMedGoogle Scholar
  71. 71.
    Common Drug Review Drug Database (Online) Canadian Agency for Drugs and Technologies in Health, Ottawa. https://www.cadth.ca/cdr/reports
  72. 72.
    Buti M, Brosa M, Casado MA, Rueda M, Esteban R (2009) Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 51:640–646CrossRefPubMedGoogle Scholar
  73. 73.
    Schedule of Laboratory Fees (Online). Government of Ontario, Toronto. http://www.health.gov.on.ca/english/providers/program/ohip/sob/lab/labfimmu.html
  74. 74.
    Wong WW, Woo G, Heathcote EJ, Krahn M (2011) Cost effectiveness of screening immigrants for hepatitis B. Liver Int 31:1179–1190CrossRefPubMedGoogle Scholar
  75. 75.
    (2004) In: Healthcare in Canada, Canadian Institute for Health Information, OttawaGoogle Scholar
  76. 76.
    Cancer Care Ontario (2014) Drug formulary. https://www.cancercare.on.ca/toolbox/drugformulary/. Accessed 04 Feb 2014
  77. 77.
    Cocquyt V, Moeremans K, Annemans L, Clarys P, Van Belle S (2003) Long-term medical costs of postmenopausal breast cancer therapy. Ann Oncol 14:1057–1063CrossRefPubMedGoogle Scholar
  78. 78.
    Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK (2000) Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 36:724–735CrossRefPubMedGoogle Scholar
  79. 79.
    Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong DKH et al (2012) Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol 26:445–451PubMedCentralPubMedGoogle Scholar
  80. 80.
    Hillner BE, Smith TJ, Desch CE (1992) Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055–2061CrossRefPubMedGoogle Scholar
  81. 81.
    Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L (2007) Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 11:iii–iv, ix–xi, 1–134Google Scholar
  82. 82.
    Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38:583–637CrossRefPubMedGoogle Scholar
  83. 83.
    Sorensen SV, Brown R, Benedict A, Flood E, Revicki D (2004) Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison. Value Health 7:641–642CrossRefGoogle Scholar
  84. 84.
    Hillner BE, Smith TJ (1991) Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 324:160–168CrossRefPubMedGoogle Scholar
  85. 85.
    Lidgren M, Wilking N, Jonsson B, Rehnberg C (2007) Health related quality of life in different states of breast cancer. Qual Life Res 16:1073–1081CrossRefPubMedGoogle Scholar
  86. 86.
    Burstrom K, Johannesson M, Diderichsen F (2006) A comparison of individual and social time trade-off values for health states in the general population. Health Policy 76:359–370CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • William W. L. Wong
    • 1
    • 2
  • Lisa K. Hicks
    • 3
  • Hong-Anh Tu
    • 4
  • Kathleen I. Pritchard
    • 5
  • Murray D. Krahn
    • 1
    • 2
    • 4
  • Jordan J. Feld
    • 6
  • Kelvin K. Chan
    • 5
  1. 1.Toronto Health Economics and Technology Assessment Collaborative (THETA)University of TorontoTorontoCanada
  2. 2.Leslie Dan Faculty of PharmacyUniversity of TorontoTorontoCanada
  3. 3.St Michael’s HospitalTorontoCanada
  4. 4.Institute of Health Policy, Management and EvaluationUniversity of TorontoTorontoCanada
  5. 5.Sunnybrook Odette Cancer CenterTorontoCanada
  6. 6.Toronto Centre for Liver DiseaseUniversity Health NetworkTorontoCanada

Personalised recommendations